Research Paper Volume 16, Issue 5 pp 4811—4831

Figure 5. FHND004 exerts anti-tumor activity in CDX and PDX mouse models. (A, B) FHND004 treatment improved the survival of MM-prone C57BL/KaLwRij mice (n = 10, i.g. 20 mg/kg, twice a week). The table at the bottom of the survival curve showed the number of subjects at risk at each time point. (C, D) Tumor images of PDX mice in the control group (PBS) and the FHND004-treated group (n = 6, FHND004: i.g. 20 mg/kg, twice a week). (E) The time course of tumor growth in the control group (PBS) and the FHND004 treated group. (F) Mean tumor weights of the control group (PBS) and the FHND004 treated group. The data were expressed as the mean ± SD; p < 0.05 (*), p < 0.01 (* *) and p < 0.001 (* * *).